Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors
- PMID: 19308787
- DOI: 10.1080/10799890902721339
Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors
Abstract
We introduce a novel experimental method to determine both the extent of ex vivo receptor occupancy of administered compound and its dissociation rate constant (k4). [Here, we reference k4 as the rate of offset of unlabeled ligand in convention with Motulsky and Mahan (1)]. We derived a kinetic rate equation based on the dissociation rate constant for an unlabeled compound competing for the same site as a labeled compound and describe a model to simulate fractional occupancy. To validate our model, we performed in vitro kinetics and ex vivo occupancy experiments in rat cortex with varying concentrations of (R)-dimethindene, a sedating antihistamine. Brain tissue was removed at various times post oral administration, and histamine H1 receptor ligand [3H]-doxepin binding to homogenates from drug-treated or vehicle-treated rats was measured at multiple time points at room temperature. Fractional occupancy and k4 for (R)-dimethindene binding to H1 receptors were calculated by using our proposed model. Rats dosed with 30 and 60 mg/kg (R)-dimethindene showed 42% and 67% occupancy of central H1 receptors, respectively. These results were comparable to occupancy data determined by equilibrium radioligand binding. In addition, drug k4 rate determined by using our ex vivo method was equivalent to k4 determined by in vitro competition kinetics (dissociation half-life t(1/2) approximately 30 min). The outlined method can be used to assess, by simulation and experiment, occupancy for compounds based on dissociation rate constants and contributes to current efforts in drug optimization to profile antagonist efficacy in terms of its kinetic drug-target binding parameters. Data described by the method may be analyzed with commercially available software. Suggested fitting procedures are given in the appendix.
Similar articles
-
In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole.Mol Pharmacol. 1982 Mar;21(2):294-300. Mol Pharmacol. 1982. PMID: 6124876
-
[Non-sedative antihistaminics and binding to central and peripheral H1 histamine receptors].Allerg Immunol (Paris). 1991 Feb;23(2):51-7. Allerg Immunol (Paris). 1991. PMID: 1677249 French.
-
Changes in pH differently affect the binding properties of histamine H1 receptor antagonists.Eur J Pharmacol. 2006 Jan 20;530(3):205-14. doi: 10.1016/j.ejphar.2005.11.051. Epub 2006 Jan 4. Eur J Pharmacol. 2006. PMID: 16388798
-
Structural Analysis of the Histamine H1 Receptor.Handb Exp Pharmacol. 2017;241:21-30. doi: 10.1007/164_2016_10. Handb Exp Pharmacol. 2017. PMID: 27826702 Review.
-
Delineation of receptor-ligand interactions at the human histamine H1 receptor by a combined approach of site-directed mutagenesis and computational techniques - or - how to bind the H1 receptor.Arch Pharm (Weinheim). 2005 Jun;338(5-6):248-59. doi: 10.1002/ardp.200400998. Arch Pharm (Weinheim). 2005. PMID: 15952243 Review.
Cited by
-
Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain.J Pharmacol Exp Ther. 2012 Nov;343(2):441-50. doi: 10.1124/jpet.112.198085. Epub 2012 Aug 16. J Pharmacol Exp Ther. 2012. PMID: 22899752 Free PMC article.
-
Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.Br J Pharmacol. 2010 Nov;161(6):1311-28. doi: 10.1111/j.1476-5381.2010.00931.x. Br J Pharmacol. 2010. PMID: 20946109 Free PMC article.
-
A two-state model for the kinetics of competitive radioligand binding.Br J Pharmacol. 2018 May;175(10):1719-1730. doi: 10.1111/bph.14184. Epub 2018 Apr 17. Br J Pharmacol. 2018. PMID: 29486053 Free PMC article.
-
Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.Naunyn Schmiedebergs Arch Pharmacol. 2012 Apr;385(4):337-72. doi: 10.1007/s00210-012-0734-2. Epub 2012 Feb 14. Naunyn Schmiedebergs Arch Pharmacol. 2012. PMID: 22331262 Review.
-
Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo.Br J Pharmacol. 2011 Oct;164(3):992-1007. doi: 10.1111/j.1476-5381.2011.01390.x. Br J Pharmacol. 2011. PMID: 21449919 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources